Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616834 · ClinicalTrials.gov registry record · Phase 2
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
A Phase 2 study, sponsored by Effector Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03616834 is a Phase 2 study that has completed, run by Effector Therapeutics. The registered enrollment target is 39 participants.
The verdict
NCT03616834, a Phase 2 study, has completed, sponsored by Effector Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.
Interventions
- DRUG Tomivosertib (eFT-508)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616834
The ClinicalTrials.gov registry entry for NCT03616834 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Effector Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tomivosertib (eFT-508) is the first listed.
NCT03616834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03616834 about?
NCT03616834 is a clinical study titled "Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy". Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.
What is the current status of trial NCT03616834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2018-07-25. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03616834?
The interventions under investigation include: Tomivosertib (eFT-508) (DRUG).
Who is sponsoring clinical trial NCT03616834?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.